XML 61 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jun. 10, 2022
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 24, 2018
USD ($)
$ / shares
$ / shares
shares
Dec. 31, 2015
USD ($)
Mar. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
Dec. 31, 2018
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
TWD ($)
Feb. 23, 2023
shares
Jul. 01, 2022
Dec. 24, 2018
$ / shares
Collaborative Agreements [Line Items]                                            
Data and development percentage                         50.00%                  
Milestone payments royalty percentage                         12.00% 12.00%                
Collaboration revenue                                     $ 50,000,000      
Cash equivalent                       $ 1,640,000   $ 100,000,000       $ 1,640,000        
Value of new shares issued                         $ 10,698 [1] $ 7,940 [1] $ 3,286              
Common stock price (in New Dollars per share) | $ / shares                     $ 50                      
Common stock per share price | (per share)                     $ 1.64   $ 0.001 [1] $ 0.001 [1] $ 0.001             $ 50
Equity method long term investment (in Shares) | shares                     1,530,000                      
Recognized investment loss                           $ (7,446)   $ 549          
Service agreement eligibility amount $ 3,000,000                                          
Milestone regulatory payment amount period 3 years                                          
Loan amount                         $ 1,000,000 $ 1,000,000                
Percentage of working capital convertible loan                         5.00% 5.00%                
Fixed conversion price equal (in Dollars per share) | $ / shares                         $ 1                  
Shares issued (in Shares) | shares                                       5,291,667    
Percentage of net sales                           5.00%                
Agreement percentage                           15.00% 10.00% 5.00%            
Outstanding amount (in Shares) | shares                             5,000,000              
Conversion of shares, description                           The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.                
BioLite Taiwan [Member]                                            
Collaborative Agreements [Line Items]                                            
Collaboration revenue                         $ 50,000,000         50,000,000        
Cash equivalent                       1,600,000 $ 1,640,000         1,600,000        
Outstanding amount (in Shares) | shares                             5,000,000              
BHK Co-Development Agreement [Member]                                            
Collaborative Agreements [Line Items]                                            
Milestone payment                 $ 31,649,000 $ 10,000,000                        
Description of payment settlement                         ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment ●Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment ●At the completion of first phase II clinical trial: $1 million, or 10% of total payment ●At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment ●Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Upfront cash payment                       $ 1,000,000           $ 1,000,000        
Data and development percentage                       10.00%                    
Total cash amount               $ 1,000,000       $ 10,000,000                    
Co-Dev Agreement [Member]                                            
Collaborative Agreements [Line Items]                                            
Data and development percentage                         50.00% 50.00%                
Cash amount             $ 3,000,000                              
Addition cash payment                         $ 3,000,000 $ 3,000,000                
Additional paid-in capital         $ 3,000,000                                  
Cash received         450,000                                  
Rgene Corporation [Member]                                            
Collaborative Agreements [Line Items]                                            
Value of new shares issued                     $ 2,550,000                      
Collaborative Agreement [Member]                                            
Collaborative Agreements [Line Items]                                            
Data and development percentage                         50.00% 50.00%                
Total cash amount       $ 3,000,000                                    
Cash amount                         $ 3,000,000 $ 3,000,000                
Licensing rights           $ 3,000,000                                
Research and development expense         $ 3,000,000                                  
BioFirst Corporation Purchase Agreement [Member]                                            
Collaborative Agreements [Line Items]                                            
Shares issued (in Shares) | shares   414,702 428,571                                      
Common stock consideration   $ 2,902,911 $ 3,000,000                                      
Rgene Corporation [Member]                                            
Collaborative Agreements [Line Items]                                            
Ownership percentage                         26.65% 26.65% 26.65%              
Ownership percentage                                         12.80%  
Rgene Corporation [Member] | Service Agreements [Member]                                            
Collaborative Agreements [Line Items]                                            
Ownership percentage                         31.62% 31.62%                
Rgene Corporation [Member] | Co-Dev Agreement [Member]                                            
Collaborative Agreements [Line Items]                                            
Ownership percentage                         6.40% 6.40%                
Rgene Studies [Member]                                            
Collaborative Agreements [Line Items]                                            
Ownership percentage                         20.00%                  
Rgene [Member]                                            
Collaborative Agreements [Line Items]                                            
Common stock per share price | $ / shares                     $ 1.6                      
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.